Mark Foley, Revance CEO (Revance via YouTube)
April 22, 2022 07:35 AM EDT
FDA+

Will a biotech ri­val fi­nal­ly shake up Ab­b­Vie's $2B Botox cos­met­ic fran­chise? Re­vance will find out soon

Amber Tong

For 20 years, Botox — short for the neu­ro­tox­ic pro­tein bot­u­linum tox­in — has reigned supreme as the most pop­u­lar cos­met­ic pro­ce­dure. Even as Evo­lus man­aged to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times